Anbio Biotechnology (NNNN) Cash & Current Investments (2023 - 2025)

Anbio Biotechnology (NNNN) has reported Cash & Current Investments for 3 consecutive years, with $11.9 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Cash & Current Investments rose 1.19% year-over-year to $11.9 million; the TTM figure through Dec 2025 stood at $11.9 million (up 1.19% YoY), while the FY2025 annual figure was $11.9 million, up 1.19% from the prior year.
• Cash & Current Investments retreated to $11.9 million in Q4 2025 per NNNN's latest filing, from $13429.0 billion in the prior quarter.
• Across five years, Cash & Current Investments topped out at $13429.0 billion in Q2 2025 and bottomed at $9.7 million in Q4 2023.
• Historically, Cash & Current Investments has averaged $3357.3 billion across 3 years, with a median of $11.8 million in 2024.
• Annual changes were most pronounced in 2024 — Cash & Current Investments gained 21.36% — and 2025, when it advanced 1.19%.
• Anbio Biotechnology's Cash & Current Investments stood at $9.7 million in 2023, then rose by 21.36% to $11.8 million in 2024, then advanced by 1.19% to $11.9 million in 2025.
• Business Quant data shows NNNN's Cash & Current Investments at $11.9 million in Q4 2025, $13429.0 billion in Q2 2025, and $11.8 million in Q4 2024.